Zenas BioPharma, Inc. $ZBIO Shares Bought by UBS Group AG

UBS Group AG lifted its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 95.8% in the fourth quarter, HoldingsChannel reports. The fund owned 69,495 shares of the company’s stock after purchasing an additional 34,003 shares during the quarter. UBS Group AG’s holdings in Zenas BioPharma were worth $2,523,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in ZBIO. Vanguard Group Inc. lifted its stake in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after acquiring an additional 290,307 shares during the period. Invesco Ltd. acquired a new stake in shares of Zenas BioPharma in the 3rd quarter worth approximately $3,237,000. Millennium Management LLC acquired a new stake in shares of Zenas BioPharma in the 3rd quarter worth approximately $1,595,000. Geode Capital Management LLC lifted its stake in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zenas BioPharma in the 4th quarter worth approximately $483,000.

Insider Activity

In other news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were acquired at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the acquisition, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at $1,636,144.64. The trade was a 162.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares of the company’s stock, valued at $47,180,500. This trade represents a 6.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 273,768 shares of company stock worth $5,150,198 over the last 90 days. 22.00% of the stock is owned by company insiders.

Zenas BioPharma Stock Down 1.3%

ZBIO stock opened at $18.73 on Wednesday. Zenas BioPharma, Inc. has a 12 month low of $8.91 and a 12 month high of $44.60. The firm has a market cap of $1.18 billion, a PE ratio of -2.21 and a beta of -0.61. The firm has a 50 day simple moving average of $20.29 and a 200 day simple moving average of $26.15. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter last year, the business earned ($0.80) EPS. Equities research analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZBIO. Morgan Stanley increased their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Guggenheim increased their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. HC Wainwright reissued a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a research note on Friday, May 15th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.